Sutro Biopharma (STRO) News Today $0.75 -0.02 (-2.64%) Closing price 04:00 PM EasternExtended Trading$0.78 +0.03 (+4.53%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Sutro Biopharma (STRO) Projected to Post Earnings on MondayMarch 22 at 1:05 AM | americanbankingnews.comHC Wainwright Lifts Earnings Estimates for Sutro BiopharmaSutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Sutro Biopharma in a research note issued to investors on Monday, March 17th. HC Wainwright analyst A. Fein now anticipates that tMarch 20, 2025 | marketbeat.comQ1 EPS Estimates for Sutro Biopharma Lifted by HC WainwrightMarch 20, 2025 | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Given Neutral Rating at HC WainwrightHC Wainwright reiterated a "neutral" rating and set a $2.00 price target (down previously from $12.00) on shares of Sutro Biopharma in a research note on Monday.March 18, 2025 | marketbeat.comHC Wainwright Reaffirms Neutral Rating for Sutro Biopharma (NASDAQ:STRO)March 18, 2025 | americanbankingnews.comSutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comSutro Biopharma (STRO) Expected to Announce Quarterly Earnings on MondaySutro Biopharma (NASDAQ:STRO) will be releasing earnings before the market opens on Monday, March 24, Financial Modeling Prep reports.March 17, 2025 | marketbeat.comCitizens Jmp Downgrades Sutro Biopharma (NASDAQ:STRO) to Market PerformMarch 17, 2025 | americanbankingnews.comSutro Biopharma presents expanded data from REFRalphaME-01 trialMarch 17, 2025 | markets.businessinsider.comSutro Biopharma (NASDAQ:STRO) Downgraded by Wedbush to "Neutral"March 16, 2025 | americanbankingnews.comBank of America Downgrades Sutro Biopharma (NASDAQ:STRO) to UnderperformMarch 16, 2025 | americanbankingnews.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | globenewswire.comWedbush Downgrades Sutro Biopharma (STRO)March 15, 2025 | msn.comSutro Biopharma (NASDAQ:STRO) Downgraded to Market Perform Rating by Citizens JmpCitizens Jmp lowered shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a research report on Friday.March 15, 2025 | marketbeat.comWedbush Downgrades Sutro Biopharma (NASDAQ:STRO) to NeutralWedbush cut shares of Sutro Biopharma from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $8.00 to $2.00 in a research report on Friday.March 15, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Lowered to "Underperform" Rating by Bank of AmericaBank of America lowered Sutro Biopharma from a "buy" rating to an "underperform" rating and cut their target price for the company from $11.00 to $1.00 in a report on Friday.March 15, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Announces Earnings ResultsSutro Biopharma (NASDAQ:STRO - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($2.96) earnings per share for the quarter. Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%.March 14, 2025 | marketbeat.comSutro Biopharma downgraded to Neutral from Overweight at Piper SandlerMarch 14, 2025 | markets.businessinsider.comSutro drops as portfolio review leads to downgradesMarch 14, 2025 | msn.comSutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2024 Financial Results and Business HighlightsMarch 14, 2025 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC PipelineMarch 14, 2025 | finanznachrichten.deSutro Biopharma downgraded to Neutral from Outperform at WedbushMarch 14, 2025 | markets.businessinsider.comSutro Biopharma double downgraded at BofA after luvelta deprioritizedMarch 14, 2025 | markets.businessinsider.comSutro Biopharma Review Results in 50% Workforce Reduction, CEO TransitionMarch 14, 2025 | marketwatch.comSutro Biopharma (STRO) was downgraded to a Hold Rating at JMP SecuritiesMarch 14, 2025 | markets.businessinsider.comSutro Biopharma rises after market hours on portfolio review, restructuringMarch 14, 2025 | msn.comSutro Biopharma Reports Full Year 2024 Financial Results and Business HighlightsMarch 13, 2025 | globenewswire.comSutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC PipelineMarch 13, 2025 | globenewswire.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Recommendation of "Moderate Buy" by AnalystsSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy reMarch 8, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. cut its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 96.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,791 shares of the company's stock after selling 1,470,550 sFebruary 19, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Average Target Price from BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has received an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the companyFebruary 14, 2025 | marketbeat.comSutro Biopharma stock hits 52-week low at $1.67 amid market challengesFebruary 11, 2025 | msn.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have issuedFebruary 11, 2025 | marketbeat.comWe're Not Very Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn RateJanuary 22, 2025 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Consensus Target Price from BrokeragesShares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on tJanuary 20, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recJanuary 17, 2025 | marketbeat.comSutro Biopharma (STRO) Gets a Buy from Bank of America SecuritiesJanuary 17, 2025 | markets.businessinsider.comSutro Biopharma: Strategic Partnerships and Promising Pipeline Drive Buy RatingJanuary 17, 2025 | markets.businessinsider.comSutro Biopharma, Inc. (NASDAQ:STRO) Sees Large Growth in Short InterestSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,150,000 shares, an increase of 28.0% from the December 15th total of 2,460,000 shares. Based on an average trading volume of 925,500 shares, the short-interest ratio is presently 3.4 days.January 16, 2025 | marketbeat.comSutro Biopharma, Boehringer announce application of Sutro’s technologyJanuary 7, 2025 | markets.businessinsider.comSutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comSutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scaleJanuary 7, 2025 | markets.businessinsider.comSutro Biopharma: I Don't Buy That Their Pipeline Is WorthlessJanuary 2, 2025 | seekingalpha.comShort Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Expands By 19.4%Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 2,460,000 shares, a growth of 19.4% from the November 30th total of 2,060,000 shares. Based on an average daily volume of 900,500 shares, the days-to-cover ratio is currently 2.7 days.December 29, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Moderate Buy" from AnalystsSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned aDecember 23, 2024 | marketbeat.comSutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measuresDecember 20, 2024 | finance.yahoo.comPromising Developments in Sutro Biopharma’s Luvelta Drive Buy RatingDecember 12, 2024 | markets.businessinsider.com Remove Ads Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address STRO Media Mentions By Week STRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STRO News Sentiment▼0.590.62▲Average Medical News Sentiment STRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STRO Articles This Week▼63▲STRO Articles Average Week Remove Ads Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cardiff Oncology News Olema Pharmaceuticals News Bright Minds Biosciences News Lifecore Biomedical News enGene News Foghorn Therapeutics News Y-mAbs Therapeutics News Nuvectis Pharma News Monopar Therapeutics News Korro Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STRO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
